Article Information
History
- December 1, 2021.
Article Versions
- Version 1 (March 10, 2021 - 18:30).
- Version 2 (May 11, 2021 - 10:25).
- Version 3 (May 13, 2021 - 08:01).
- Version 4 (June 24, 2021 - 12:16).
- Version 5 (July 26, 2021 - 10:28).
- Version 6 (August 6, 2021 - 15:49).
- Version 7 (September 30, 2021 - 09:44).
- You are currently viewing Version 8 of this article (December 1, 2021 - 21:27).
- Version 9 (December 7, 2021 - 12:57).
- Version 10 (December 15, 2021 - 15:44).
- Version 11 (February 18, 2022 - 05:37).
- View Version 12, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Andrea L. Cathcart1,
- Colin Havenar-Daughton1,
- Florian A. Lempp1,
- Daphne Ma1,
- Michael A. Schmid2,
- Maria L. Agostini1,
- Barbara Guarino2,
- Julia Di iulio1,
- Laura E. Rosen1,
- Heather Tucker1,
- Joshua Dillen1,
- Sambhavi Subramanian1,
- Barbara Sloan1,
- Siro Bianchi2,
- Dora Pinto2,
- Christian Saliba2,
- Jason A Wojcechowskyj1,
- Julia Noack1,
- Jiayi Zhou1,
- Hannah Kaiser1,
- Arthur Chase1,
- Martin Montiel-Ruiz1,
- Exequiel Dellota Jr.1,
- Arnold Park1,
- Roberto Spreafico1,
- Anna Sahakyan1,
- Elvin J. Lauron1,
- Nadine Czudnochowski1,
- Elisabetta Cameroni1,
- Sarah Ledoux1,
- Adam Werts3,
- Christophe Colas1,
- Leah Soriaga1,
- Amalio Telenti1,
- Lisa A. Purcell1,
- Seungmin Hwang1,
- Gyorgy Snell1,
- Herbert W. Virgin1,
- Davide Corti2 and
- Christy M. Hebner1,*
- 1Vir Biotechnology, San Francisco, California 94158, USA
- 2Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
- 3Lovelace Biomedical, Albuquerque, New Mexico 87108, USA
- ↵*corresponding author: chebner{at}vir.bio
Posted December 01, 2021.
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
